Novo Nordisk, the pharmaceutical giant, has revealed preliminary study results showing that its weight loss pill performed better than blockbuster shots.
Study participants who took the medication, called amyretin, lost 13 percent of their body weight over 12 weeks, exceeding the amount of weight lost from its obesity jab Wegovy, which was 6 percent over the same time period.
The groundbreaking results, which have not yet been stood up by strict scientific scrutiny, propelled the company to the ranking of 12th most valuable company with a valuation of $566 billion, surpassing that of Tesla and Visa.
The Danish drug maker, along with Eli Lilly, run what is essentially a duopoly on the obesity medicine market, and both have struggled to meet soaring demand for their highly effective monthly diet shots.
The obesity pill led to more weight loss in the same 12 weeks span as the company’s groundbreaking injectable Wegovy
